Adults with weight problems who regained weight after bariatric surgical procedure noticed more practical weight reduction with GLP-1 receptor agonist remedy in contrast with different weight-loss regimens, in keeping with knowledge printed in Obesity.
“There are a number of drugs which might be accepted for weight administration (phentermine, topiramate-phentermine, orlistat, bupropion-naltrexone and liraglutide); nonetheless, there are restricted knowledge to assist their use to deal with post-bariatric weight regain,” Chellse L. Gazda, MD, assistant professor within the division of inside drugs at University of Texas Southwestern Medical Center, and colleagues wrote within the research background. “Liraglutide is a GLP-1 receptor agonist that’s accepted for managing kind 2 diabetes mellitus and weight problems. Studies have proven that postprandial ranges of endogenous GLP-1 after bariatric surgical procedure could be 10 to twenty instances larger in contrast with earlier than surgical procedure.”
In a retrospective research, Gazda and colleagues analyzed knowledge from 207 adults handled for weight regain after bariatric surgical procedure at a tutorial middle from January 2014 to November 2019. Researchers in contrast the proportion of physique weight reduction after 3, 6, 9 and 12 months of remedy amongst adults who acquired intensive life-style modification, non-GLP-1 receptor agonist pharmacotherapy or GLP-1 receptor agonists as a part of a weight-loss program, with each pharmacotherapy teams additionally using intensive life-style modification.
Researchers discovered that the proportion of physique weight reduction differed by remedy kind at 3, 6 and 9 months. At 3 months, adults who acquired life-style modification, non-GLP-1 receptor agonist medicine or GLP-1 receptor agonist remedy skilled imply weight lack of 1.4%, 2.2% and 4.5%, respectively (P < .001). At 6 months, imply weight-loss share was 0.8% for adults who acquired life-style modification, 2.9% for individuals who acquired non-GLP-1 receptor agonist medicine and 6.7% for individuals who acquired GLP-1 receptor agonist remedy, (P < .001), and 1.6%, 5.6% and 6.9% throughout the three remedy teams, respectively, at 9 months (P = .007).
“There was a major distinction within the share of people reaching a minimum of 5% weight reduction after 3, 6 and 9 months, with most occurring within the GLP-1 receptor agonist-based weight-loss program group,” the researchers wrote.
At 12 months, the proportion of weight reduction was numerically however not statistically important.
In a number of regression evaluation, researchers discovered the outcomes didn’t change when stratified by bariatric surgical procedure kind, including that remedy group was the one important predictor of share weight change.
“Based on our research, a GLP-1 receptor agonist-based weight-loss program seems to be superior to non-GLP-1 receptor agonist-based weight-loss applications and intensive life-style modification alone for treating post-bariatric surgical procedure weight regain, no matter surgical procedure kind,” the researchers wrote. “However, bigger potential randomized research are wanted to establish the optimum remedy methods for post-bariatric weight regain, which is a frequent problem on this rising inhabitants.”